Azra AI and Riverain Technologies Collaborate to Integrate Advanced AI for End-to-End Lung Cancer Detection and Care Coordination

Nashville, TN – [October 1, 2025] –  Azra AI, the industry’s only end-to-end platform that automates workflows and coordinates care across oncology and other critical service lines, and Riverain Technologies, a pioneer in AI-powered lung imaging, today announced a new collaboration to deliver a seamless patient experience from first image-based detection through survivorship.

Lung cancer remains the leading cause of cancer deaths worldwide, often because patients fall through the cracks between detection and treatment. This collaboration closes those gaps by integrating Riverain’s ClearRead™ imaging solutions—trusted by radiologists globally to improve early detection and reading efficiency—with Azra AI’s real-time pathology and radiology analysis, automated care coordination, and survivorship management. Together, the companies offer the first solution that unites image detection of solid, sub-solid, and ground-glass nodules, radiology and pathology reports, navigation, and advanced analytics into one connected ecosystem. By getting AI findings into a single solution and extending advanced analytics across the continuum, Riverain and Azra AI bridge the divide between radiology, pulmonology, and oncology—something no other patient-management system can do, as most stop at detection. The result is a seamless experience that helps health systems accelerate diagnosis, reduce time to treatment, and support patients through every phase of their cancer journey.

“Together, Azra AI and Riverain are ensuring that lung cancer patients don’t just get detected, they get connected to care faster and supported across their entire journey,” said John Marshall, CEO of Azra AI. “This partnership creates true end-to-end visibility, empowering providers to deliver better clinical outcomes while strengthening health system performance.”

“Riverain has always helped radiologists see clearly so they can save lives,” said Steve Worrell, CEO of Riverain Technologies. “Partnering with Azra AI extends that clarity beyond the scan, uniting two leaders to give health systems a tailored, robust plan for the entire continuum of lung cancer care, not just another set of products.”

In addition to advancing clinical care, this collaboration equips health systems with comprehensive analytics spanning the full continuum of lung cancer. Leaders gain actionable insights to strengthen compliance, improve patient retention, and drive measurable financial impact.

About Azra AI

Azra AI is a healthtech firm transforming oncology care with the industry’s only end-to-end oncology service line platform. Our AI-driven solution analyzes pathology and radiology reports in real-time, enabling hospitals and cancer centers to identify cancer diagnoses, suspicious incidental findings, and high-risk screenings earlier, connect patients to treatment sooner, and manage their care journey efficiently. By automating oncology workflows, Azra AI reduces time to treatment, improves operational efficiency, and delivers measurable ROI. Learn more or schedule a demo at www.azra-ai.com/get-a-demo.

About Riverain Technologies

Riverain Technologies is dedicated to transforming the field of radiology by addressing and eliminating delayed cardiothoracic diagnoses. As relentless innovators, Riverain empowers healthcare providers by streamlining diagnostic workflows, enhancing detection accuracy, and ultimately improving patient outcomes. With a steadfast commitment to advancing cardiothoracic care, Riverain Technologies is shaping the future of diagnostic excellence. For more information: https://www.riveraintech.com/